Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharmaceutical Group Co., Ltd. experienced notable stock activity, reaching an intraday high while the broader market declined. The company reported impressive net profit growth and strong operating cash flow, alongside a significant reduction in raw material costs, reinforcing its competitive position in the pharmaceuticals sector.

Haisco Pharmaceutical Group Co., Ltd. has recently experienced a change in evaluation, reflecting a complex analysis of its technical indicators and market position. While short-term trends show cautious optimism, the company faces challenges in long-term growth metrics, including modest profit growth and a relatively high price-to-book value.

Haisco Pharmaceutical Group Co., Ltd. has shown strong stock performance, gaining 7.46% on March 27, 2026, and outperforming the China Shanghai Composite over various timeframes. The company has achieved significant long-term growth, with a 134.64% increase over three years and a 238.07% rise over the past decade.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock decline on March 23, 2026, amid a challenging trading session. Despite recent fluctuations, the company has shown strong annual returns and impressive long-term growth, although it faces valuation challenges with a high price-to-earnings ratio and modest return on equity.

Haisco Pharmaceutical Group Co., Ltd. saw a significant intraday increase on March 17, 2026, contrasting with a decline in the broader market. The company has shown positive weekly and monthly trends, with impressive annual returns, though it faces challenges with a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. has seen significant stock performance, rising 5.46% today and achieving an intraday high of CNY 49.18. Over the past year, the company has gained 41.65%, outperforming the broader market, while maintaining a strong long-term growth trajectory with substantial increases over three and five years.

Haisco Pharmaceutical Group Co., Ltd. has seen notable stock activity, achieving an intraday high and a weekly gain of over 10%. Despite a year-to-date decline, the company boasts a strong one-year performance and a market capitalization of CNY 25,698 million, with a price-to-earnings ratio of 141.00.

Haisco Pharmaceutical Group Co., Ltd. saw a significant stock increase today, contrasting with the modest rise of the China Shanghai Composite. Over the past year, Haisco has achieved a strong annual return, despite a year-to-date decline, and maintains a notable market capitalization within the Pharmaceuticals & Biotechnology sector.

Haisco Pharmaceutical Group Co., Ltd. faced a significant decline in stock performance, with a notable drop today and over the past week. Despite a challenging year-to-date performance, the company has shown substantial growth over three and five years. Key financial metrics reflect a high price-to-earnings ratio and modest dividend yield.

Haisco Pharmaceutical Group Co., Ltd. faced a decline in stock performance, with a notable drop today and a significant decrease over the past week. Year-to-date, the stock has decreased, contrasting with broader market gains. The company has a high price-to-earnings ratio and a modest dividend yield, indicating a complex financial landscape.